-
Mashup Score: 1
Extrachromosomal DNA was highly expressed in 18 DLBCL cell lines, especially relapsed or refractory cases, and may function as a powerful prognostic indicator.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
“We determined that two common and easily measured blood tests can identify in advance which [DLBCL] patients are at high risk for poor outcomes after treatment with CD19-targeted CAR-T cells,” said Marco Davila, MD, PhD. Keep reading: https://t.co/7pT5U3vaDl @MarcoLDavila #DLBCL https://t.co/sGYZjNwLYK
-
-
Mashup Score: 0
The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
“We determined that two common and easily measured blood tests can identify in advance which [DLBCL] patients are at high risk for poor outcomes after treatment with CD19-targeted CAR-T cells,” said Marco Davila, MD, PhD. Keep reading: https://t.co/7pT5U3vaDl @MarcoLDavila #DLBCL https://t.co/sGYZjNwLYK
-
-
Mashup Score: 10Krish Patel, MD, Talks Gilteritinib, Other Novel Frontline Therapies in DLBCL | Blood Cancers Today - 22 day(s) ago
“Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 8Krish Patel, MD, Talks Gilteritinib, Other Novel Frontline Therapies in DLBCL | Blood Cancers Today - 22 day(s) ago
“Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
“We determined that two common and easily measured blood tests can identify in advance which [DLBCL] patients are at high risk for poor outcomes after treatment with CD19-targeted CAR-T cells,” said Marco Davila, MD, PhD. Keep reading: https://t.co/7pT5U3vaDl @MarcoLDavila #DLBCL https://t.co/sGYZjNwLYK
-
-
Mashup Score: 4
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
“We determined that two common and easily measured blood tests can identify in advance which [DLBCL] patients are at high risk for poor outcomes after treatment with CD19-targeted CAR-T cells,” said Marco Davila, MD, PhD. Keep reading: https://t.co/7pT5U3vaDl @MarcoLDavila #DLBCL https://t.co/sGYZjNwLYK
-
-
Mashup Score: 4
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
“We determined that two common and easily measured blood tests can identify in advance which [DLBCL] patients are at high risk for poor outcomes after treatment with CD19-targeted CAR-T cells,” said Marco Davila, MD, PhD. Keep reading: https://t.co/7pT5U3vaDl @MarcoLDavila #DLBCL https://t.co/sGYZjNwLYK
-
-
Mashup Score: 6
ECHELON-3 trial of ADCETRIS in combination with lenalidomide and rituximab showed significant improvement in primary endpoint of overall survival and in secondary endpoints of progression free survival and overall response rate versus lenalidomide and rituximab plus placebo, regardless of CD30 expression Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS Pfizer Inc. (NYSE: PFE) today announced that a Phase 3 study of the antibody-drug conjugate ADCETRIS ® (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) showed a statistically significant and clinically meaningful improvement in overall survival (OS) compared to lenalidomide and rituximab plus placebo. Positive outcomes were also observed in key secondary endpoints, including progression free survival (PFS) and overall response rate (ORR). The safety and tolerability of
Source: www.pfizer.comCategories: General Medicine News, PayerTweet
A multiomics analysis shows how inhibiting a gene signaling pathway might work in treating #DLBCL. Researchers theorize that circular DNA independent of chromosomes is involved in cancer cell development, disease heterogeneity, and drug resistance. 🧬📰 https://t.co/eaQhx5hwfb https://t.co/xVQE5m2hWA